key: cord-0923969-fq3imuyp authors: Connor, Bradley A.; Couto-Rodriguez, Mara; Barrows, Joseph E.; Gardner, Morgan; Rogova, Marina; O'Hara, Niamh B.; Nagy-Szakal, Dorottya title: Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case date: 2021-07-13 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.07.029 sha: aca487ded4160dc26e1137789ba17ae9c4359141 doc_id: 923969 cord_uid: fq3imuyp We present two Delta (B.1.617.2) vaccine breakthrough individuals, a father and son living in separate households. The older, 63-year-old patient's symptoms were severe enough to require hospitalization. Despite having a high titer of anti-spike IgG in his serum, his symptoms resolved within 24 hours following monoclonal antibody (bamlanivimab/etesevimab) therapy. The SARS-CoV-2 Delta variant of concern (B.1.617.2, 20A/S:478K), originating in India and now emerging in the United States, has been shown to have increased transmissibility and a reduction in neutralization to some monoclonal antibody (mAb) treatments and post-vaccination sera (Centers for Disease Control and Prevention, 2021) . To date, the vast majority of vaccine breakthrough cases have been mild or asymptomatic (Fischer et al., 2021) . We present Delta variant vaccine breakthrough cases in a father and son, with hospitalization of the father which occurred despite a high level of IgG detected in the patient's serum, and resolution of symptoms within 24 hours following mAb therapy. A 63-year-old man (Patient A) with a history of mild hypertension, benign prostatic hypertrophy, and a body mass index of 27, was found to be SARS-CoV-2 positive by reverse transcription polymerase chain reaction (RT-PCR) on June 3, 2021. His 25-year-old son (Patient B), who he had seen the previous weekend, had developed upper respiratory symptoms and headaches 6 days earlier, also had a SARS-CoV-2 positive PCR on June 3, 2021. Although Patient A was asymptomatic at the time of testing, he developed nasal congestion, headache, and a dry cough the following day. These symptoms became more pronounced over the next few days,and were associated with extreme fatigue and lassitude. His SPO2 was consistently above 98% by self-monitoring, except for a transient drop to 95%. Both patients had previously received two doses of COVID-19 vaccine BNT162b2 (Pfizer-BioNTech, LOT# EM9810, EN6207) 22 days apart in March and April of 2021. Sinai Hospital in New York City. His vital signs were stable and he was afebrile. A SARS-CoV-2 IgG semi-quantitative anti-spike protein antibody was a -strong positive‖ at 178 AU/ml (negative <5AU/ml), suggesting a strong immune response to the vaccine. He received mAb infusion (bamlanivimab/etesevimab) and was discharged. He reported feeling a returned sense of well-being with complete resolution of symptoms by the next morning. The close contacts of both patients remained asymptomatic and were negative by repeat SARS CoV-2 PCR testing. The SARS-CoV-2 positive clinical specimens (nasopharyngeal swabs) were further tested by RT-PCR and next-generation sequencing (NGS). COVID-DX software (Biotia) was used to detect genetic variants, define PANGO lineage, and assess cladelevel phylogenetic analysis. Notably, we detected two spike protein deletions in Patient A that were not present in Patient B (H69_V70del (ATACATG21764A) and Y145del (TTTA21990T). The patients provided informed consent to provide specimen and clinical metadata, and the samples were processed under Protocol Number 00042824 (Advarra Institutional Review Board). To our knowledge, this is the first known Delta variant vaccine breakthrough case with hospitalization in New York City. Interestingly, the two vaccine breakthroughs in the same family with similar variant profiles of the SARS-CoV-2 virus may be related to host genetics or the specific mutations of a shared virus. At hospitalization, the patient described no fever, no loss of smell or taste, and no shortness of breath, presenting a clinical picture related to Delta variant cases. Despite his SARS CoV-2 IgG being strongly positive, he was treated with mAb (bamlanivimab/ etesevimab) and his symptoms resolved quickly. The mAb therapy potentially influenced the patient's clinical course as within 12 hours of receiving this therapy the patient got better and within 24 hours he was completely free of all symptoms he had been suffering within the previous three days. Bamlanivimab and etesevimab combined therapy has been issued Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the treatment of mild and moderate COVID-19 who are at high risk for progressing to severe COVID-19 and/or hospitalization (U.S. Food and Drug Administration, 2021). However, to date, there is no reported usage of mAb therapy for individuals with high anti-spike IgG serum level. Additionally, reduction of susceptibility to different variants such as E484K using mAb therapy has been reported but susceptibility to variants in B.1.617.2 has not been determined. A recent study suggests that there were only modest differences in vaccine effectiveness with the Delta variant compared to other variants after 2 doses of BNT162b2 (Bernal et al., 2021; Davis et al., 2021) . Genomic surveillance of novel variants in SARS-CoV-2 positive cases, especially vaccine breakthrough cases, as well as collection of related clinical metadata and therapeutic outcomes, will be necessary to fight the virus as it continues to evolve. BAC, MCR, JEB, NBO, and DNS work with Biotia, a for-profit biotechnology company. We acknowledge funding support from the GeoSentinel Foundation, Inc. The study sponsor had no role in the study design and completion of the publication. We also thank Jefferson Garcia for PCR laboratory support, Xavier Jirau Serrano for NGS work, Marilyne Debieu for IT support, Christopher E Mason for NGS development guidelines, and Courteny Hager for operational and management support. The plot shows the depth of sequencing that was recovered across the genome. We detected 35 mutations, including 12 ORF1ab, 9 spike protein, Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv 2021 SARS-CoV-2 Variant Classifications and Definitions Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. medRxiv COVID-19 Vaccine Breakthrough Infections Reported to CDC -United States The spike protein mutations include: C21618G (T19R) TTTA21990T (Y145del), T22917G (L452R), C22995A (T478K) The percent of the SARS-CoV-2 genome recovered from the sample and genetic variants identified compared to the reference genome (Wuhan wild-type strain) are indicated (top) with no coverage (pink), and higher callable coverage (blue) shown. The proportion of known genetic variants of SARS-CoV-2 strains as reported in NextStrain BAC, MCR, JEB, NBO, and DNS work with Biotia, a for-profit biotechnology company.